Dr David E Elder
Professor of Pathology and Laboratory Medicine University Hospital of Pennsylvania.
10.00 - 10.15: Welcome
10.15 - 11.00: 2018 WHO Classification of melanoma
11.00 - 11.30: Coffee
11.30 - 12.15: Diagnosis and significance of dysplastic nevi
12.15 - 13.00: Lunch
13.00 - 13.45: Diagnostic accuracy and reproducibility of melanocytic tumors - the MPath project
13.45 - 14.15: Coffee
14.15 - 15.00: Superficial atypical melanocytic proliferations
15.00 - 15.30: Discussion and round up
To provide a comprehensive update on the latest WHO Classification of melanomas and difficult superficial melanocytic tumors including dysplastic nevi. The emphasis is on morphology including presentation of the Mpath-Dx scheme, a melanocytic pathology assessment tool and hierarchy for diagnosis.
The topics are directed mainly at surgical pathologists, but also at clinicians with interest in melanoma pathology
David E Elder, MB CHB, FRCPA.
Dr. Elder is Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania and currently leads its Dermatopathology Program within the Section of Surgical Pathology. In 2004 he was made a Distinguished Fellow of the Royal College of Pathologists of Australasia and in 2011 he was honored with a Life Membership of the British Society for Dermatopathology. He is a founding member of the Penn Melanoma and Pigmented Lesion Study Group since 1978 and a leading member of the Melanoma Genetics Consortium (Genomel), serving as Principal Investigator of an NIH grant supporting this program for 10 years.
Dr. Elder has served as the Lead Editor for the latest revision of the 2018 4th Edition WHO “Blue Book” on Classification of Skin Tumours. He has authored or edited several highly esteemed textbooks, including the Atlas and Synopsis of Lever’s Histopathology of the Skin, and has published over 200 peer-reviewed scientific articles and reviews. Dr. Elder continues to pursue his interests in the classification and diagnosis of skin disease and in particular diagnosis and prognosis of melanoma and other melanocytic tumors, and regularly participates in the clinical activities of his specialty at Penn.
Email to: email@example.com
before September 3, 2019. Please quote name, department and hospital at registration.
Participation in the seminar, coffe/tea and a sandwich for lunch is free made possible by generous sponsorships from the Danish Cancer Society and Danish Melanoma Group (DMG).
Information will also be available at the Danish Melanoma Group homepage: